1
Home
Companies

DICE Therapeutics

#3741

Rank

$2.22B

Marketcap

US United States

Country

DICE Therapeutics
Leadership team

Dr. J. Kevin Judice Ph.D. (Founder, CEO & Director)

Mr. Scott Robertson (Chief Bus. & Financial Officer)

Dr. Timothy Lu M.D., Ph.D. (Chief Medical Officer)

Products/ Services
Biotechnology, Medical, Medical Device
Number of Employees
50 - 100
Headquarters
San Francisco, California, United States
Established
2013
Company Registration
SEC CIK number: 0001645569
Traded as
DICE
Social Media
URL
https://www.dicemolecules.com
Overview
Location

Summary
History
Mission
Vision
Key Team
Recognition and Award
References
Summary
DICE Therapeutics, Inc., a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Its platform DELSCAPE, is designed to discover selective oral small molecules to modulate protein-protein interactions (PPIs) as effectively as systemic biologics. The company's lead therapeutic candidate is DC-806, an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17, which is a validated drug target implicated in a various immunology indications. It is also developing oral therapeutic candidates targeting a4ß7 integrin for the treatment of inflammatory bowel diseases, as well as targeting aVß1/aVß6 integrin for the treatment of idiopathic pulmonary fibrosis. In addition, the company focuses on immuno-oncology for antibody therapeutics. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
History

DICE Therapeutics was founded in 2018 with a vision to simplify and improve existing drug delivery methods. By 2020, DICE had mounted a successful clinical trial program for its lead delivery platform, becoming a leader in the space of drug delivery innovation.

Mission
Our mission is to deliver breakthrough therapies that improve the quality of life and generate value for our customers and partners.
Vision
Our vision is to establish ourselves as the go-to company for drug delivery innovations and be the partner of choice in transforming treatments and therapeutics into groundbreaking treatments.
Key Team

Ms. Mary Riley J.D. (Gen. Counsel)

Dr. John R. Jacobsen Ph.D. (Chief Scientific Officer)

Mr. Venkat Thalladi Ph.D. (Sr. VP of CMC)

Mr. Paul Fatheree (Sr. VP of Medicinal Chemistry)

Recognition and Awards
DICE Therapeutics has been recognized as a Global Top 30 Innovator and the winner of multiple awards in the field of drug delivery and innovation.
References

https://in.investing.com/equities/dice-molecules-holdings-llc

https://finance.yahoo.com/quote/DICE/profile?p=DICE

https://www.crunchbase.com/organization/dice-molecules

https://companiesmarketcap.com/

https://www.dicemolecules.com

Dive deeper into fresh insights across Business, Industry Leaders and Influencers, Organizations, Education, and Investors for a comprehensive view.

DICE Therapeutics
Leadership team

Dr. J. Kevin Judice Ph.D. (Founder, CEO & Director)

Mr. Scott Robertson (Chief Bus. & Financial Officer)

Dr. Timothy Lu M.D., Ph.D. (Chief Medical Officer)

Products/ Services
Biotechnology, Medical, Medical Device
Number of Employees
50 - 100
Headquarters
San Francisco, California, United States
Established
2013
Company Registration
SEC CIK number: 0001645569
Traded as
DICE
Social Media
URL
https://www.dicemolecules.com